Table 1.
Spearman coefficient of correlation between DAS28-ESR and CDAI or SDAI during treatment with TCZ or MTX
| Indices of disease activity | Weeks after the first treatment | ||||
|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | 24 | |
| DAS28-ESR vs. CDAI | |||||
| TCZ | 0.818 | 0.842 | 0.822 | 0.890 | 0.823 |
| MTX | 0.883 | 0.865 | 0.911 | 0.921 | 0.887 |
| DAS28-ESR vs. SDAI | |||||
| TCZ | 0.854 | 0.861 | 0.831 | 0.900 | 0.838 |
| MTX | 0.893 | 0.869 | 0.902 | 0.930 | 0.897 |
DAS28-ESR 28-joint disease activity score using erythrocyte sedimentation rate, CDAI, SDAI, clinical and simplified disease activity indices, respectively, TCZ tocilizumab, MTX methotrexate